Jiménez-Jiménez Ana Belén, Galán-Sánchez Fátima, Hortelano Milagros García-López, Fumadó Victoria, Salar-Vidal Llanos, Ramos-Amador José Tomás, Menasalvas-Ruiz Ana Isabel
Pediatric Department, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria FJD, Madrid, Spain.
Universidad Autónoma de Madrid, Spain.
Rev Esp Quimioter. 2025 Jul 3;38(4):258-277. doi: 10.37201/req/026.2025.
Acute infectious diarrhea is a major global health issue, especially in children, as gastrointestinal infections are the second most common infectious disease after respiratory infections. The implementation of rapid multiplex molecular syndromic panels (RMMSP) for the comprehensive detection and identification of enteric pathogens in stool samples has enhanced diagnostic precision, supplementing-or, in some cases, replacing-traditional methodologies. This narrative, non-systematic review synthesized the available evidence on the clinical performance of gastrointestinal RMMSP up to December 31, 2024. On May 27, 2024, specialists in Pediatrics and Microbiology met to assess the use of RMMSP in pediatric gastrointestinal infection diagnosis. This review focused on RMMSP applicable to urgent management of infectious acute gastroenteritis (AGE), excluding those panels unsuitable for immediate diagnosis. RMMSP facilitated rapid pathogen detection in pediatric infectious AGE and have shown potential advantages over traditional microbiological methods, including a reduction in time to appropriate treatment. Their use appeared particularly useful in emergency and inpatient settings for inflammatory AGE, prolonged traveler's diarrhea, or cases at risk for complications. They were also considered for outpatient diagnosis in moderate/severe cases, chronic diarrhea, or immunocompromised patients. Within a diagnostic stewardship framework, current evidence suggests that RMMSP can contribute to minimizing unnecessary testing and hospitalizations, improving outbreak control, and optimizing antimicrobial use. However, further research is necessary to refine diagnostic workflows and ensure timely result delivery. This document evaluated key aspects regarding the application of RMMSP in pediatric infectious AGE, aiming to establish standardized protocols, support clinical decision-making, and facilitate optimal patient management.
急性感染性腹泻是一个重大的全球健康问题,在儿童中尤为突出,因为胃肠道感染是仅次于呼吸道感染的第二常见传染病。实施快速多重分子综合征检测板(RMMSP)用于全面检测和鉴定粪便样本中的肠道病原体,提高了诊断的准确性,补充了——在某些情况下,还取代了——传统方法。本叙述性非系统性综述综合了截至2024年12月31日关于胃肠道RMMSP临床性能的现有证据。2024年5月27日,儿科和微生物学专家会面,评估RMMSP在儿科胃肠道感染诊断中的应用。本综述重点关注适用于感染性急性胃肠炎(AGE)紧急管理的RMMSP,不包括那些不适用于即时诊断的检测板。RMMSP有助于在儿科感染性AGE中快速检测病原体,并且已显示出相对于传统微生物学方法的潜在优势,包括缩短至适当治疗的时间。它们在炎症性AGE、长期旅行者腹泻或有并发症风险的病例的急诊和住院环境中似乎特别有用。对于中度/重度病例、慢性腹泻或免疫功能低下患者的门诊诊断也考虑使用它们。在诊断管理框架内,目前的证据表明RMMSP有助于最大限度地减少不必要的检测和住院,改善疫情控制,并优化抗菌药物的使用。然而,需要进一步研究以完善诊断工作流程并确保及时提供结果。本文评估了RMMSP在儿科感染性AGE中的应用的关键方面,旨在建立标准化方案,支持临床决策,并促进最佳的患者管理。